Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide plus anastrozole in boys with testotoxicosis
2012-001180-77Phase 2
- Sponsor
- AstraZeneca
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bicalutamide and anastrozole in Familial male-limited gonadotropin-independent precocious puberty (FMPP) and Peripheral precocious puberty (PPP), sponsored by AstraZeneca. Primary endpoint: Change in growth rate.
02
Drugs
bicalutamideanastrozole
03
Conditions
Familial male-limited gonadotropin-independent precocious puberty (FMPP)Peripheral precocious puberty (PPP)
Beyond the preview
Go deeper on 2012-001180-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001180-77.